NOVANTA INC (NOVT) Form 8-K — Jul 27, 2026

$NOVTForm 8-KItems 2.01, 2.03, 7.01, 9.01Filed Jul 27, 2026, 8:15 AM ET0001193125-26-316947Original filing

Novanta Inc. completed the acquisition of Riverpoint Medical from Arlington Capital Partners for approximately $1.2 billion in cash, with an additional $250 million milestone payment due by January 8, 2027. To fund the transaction, Novanta borrowed $616 million under its revolving credit facility and delayed draw term loan facility, with total consolidated debt now at $854.7 million. The acquisition is expected to double Novanta's recurring medical consumables revenue to approximately $300 million and increase medical end-market exposure to 60% of total revenue.

Key figures

Total Debt: $854.7 million
Debt Amount: $616.0 million
Deal Value Usd: $1.2 billion
Maturity Date: June 2030
Gross Proceeds: $1.2 billion
Milestone Payment: $250.0 million
Eps Contribution2027: $0.18-$0.25
Medical End Market Exposure: 60%
Incremental Addressable Market: $2 billion
Recurring Medical Consumables Revenue: $300 million

Price after filing

1 day: +0.6%7 days: +5.4%30 days: -0.8%

Close on the filing date to close N calendar days later (from $140.80). Historical, not a forecast.

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.